Summary
The treatment of advanced breast cancer has undergone relatively little change in the past decade. Reasons for such a static situation are the sobering realization that even effective chemotherapeutic regimens have had a minor impact on survival, and the paucity of new effective agents that have been introduced since initial combination treatments. Based in part on this lack of progress, in recent yearsdose-intensification in search of a curative strategy has been widely adopted. Its role remains to be defined, but ultimately it is likely to be relegated to situations where tumor burdens have been effectively reduced. This reduction in burden may not currently be feasible in many advanced presentations. Outpatient efforts will therefore focus on the following: 1) employing single agents optimally (e.g. infusion 5-fluorouracil), 2) using regimens which integrate new drugs with activity (e.g. taxol), and 3) testing measures which may improve the quality of life (e.g. bisphosphonates in the presence of bone metastases).
Although one cannot approach the treatment of advanced breast cancer with the (misplaced) optimism of two decades ago, the expanded armamentarium currently available should lead to a more rational application of chemotherapy. Treatments will increasingly be based on the biology of the cancer, and on the therapeutic index and action of the drugs.
Similar content being viewed by others
Abbreviations
- ASCO:
-
American Society of Clinical Oncology
- ECCO:
-
European Conference on Clinical Oncology
- ESMO:
-
European Society of Medical Oncology
- CMFVP:
-
C, cyclophosphamide; M, methotrexate; F, 5-fluorouracil; V, vincristine; P, prednisone;
- FAC, CAF, AC:
-
A, adriamycin; H, hexamethylmelamine; D, dibromodulcitol
- CEA:
-
carcinoembryonic antigen
References
Cote RJ, Rosen PP, Lessen ML: Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J Clin Oncol 9:1749–1756, 1991
Bonadonna G, Veronesi U, Brambilla C, Ferrari L, Luini A, Greco M, Bartoli C, Coopman de Yoldi G, Zucali R, Rilke R, Andreola R, Silvestrini R, Di Fronzo G, Valagussa P: Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 82:1539–1545, 1990
Rubens RD (ed): The Management of Bone Metastases and Hypercalcemia by Osteoclast Inhibition. Hogrefer & Huber, Toronto, 1990, pp 9–123
Fisher B, Anderson S, Fisher ER, Redmond C, Wickerham DL, Wolmark N, Mamounas EP, Deutsch M, Margolese R: Significance of ipsilateral tumour recurrence after lumpectomy. Lancet 338:327–331, 1991
Cooper RG: Combination chemotherapy in hormone resistant breast cancer. Proc Am Assoc Cancer Res 10:15, 1969
Canellos GP, DeVita V, Gold GL: Cyclical combination chemotherapy for advanced breast carcinoma. Br Med J 1:218–220, 1974
Fisher B, Redmond C, Fisher ER, Wolmark N: Systemic adjuvant therapy in treatment of primary operable breast cancer: National Surgical Adjuvant Breast and Bowel Project experience. NCI Monogr 1:35–43, 1986
Fisher B, Redmond C, Poisson S, Dimitrov N, Margolese R, Bowman D, Glass A, Robidoux A, Wickerham D, Wolmark N, Jochimsen P: Increased benefit from addition of adriamycin and cyclophosphamide to tamoxifen (Tam) for positive-node, Tam-responsive postmenopausal breast cancer patients: results from NSABP B-16. Proc Am Soc Clin Oncol 9:20, 1990
Tannock IF, Boyd NF, De Boer G, Erlichman C, Finse S, Larocque G, Mayers C, Perrault D, Sutherland H: A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 6:1377–1387, 1988
Speyer JL, Green MD, Kramer E, Rey M, Sanger J, Ward C, Dubin N, Ferrans V, Stecy P, Zeleniuch-Jacquotte A, Wernz J, Feit F, Slater W, Blum R, Muggia F: Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 319:745–752, 1988
Hainsworth JD, Andrews MB, Johnson DH, Greco FA: Mitoxantrone, fluorouracil, and high-dose leucovorin: an effective, well-tolerated regimen for metastatic breast cancer. J Clin Oncol 9:1731–1736, 1991
Jones SE, Mennel RG, Brooks B, Westrick MA, Allison MA, Paulson RS, Tilmann K, Rae B: Phase II study of mitoxantrone, leucovorin and infusional fluorouracil for treatment of metastatic breast cancer. J Clin Oncol 9:1736–1739, 1991
Hart R, Perloff M, Holland J: 1-day VATH (Vinblastine, Adriamycin, Thiotepa, Halotestin) therapy for advanced breast cancer refractory to chemotherapy. Cancer 48:1522–1527, 1981
Henderson IC: Chemotherapy for advanced disease. In: Harris JR, Hellman S, Henderson IC, Kinne DW (eds) Breast Diseases. JB Lipincott, Philadelphia, 1987, pp 429–479
Ahmann DL, et al: The effect on survival of initial chemotherapy in advanced breast cancer polychemotherapy versus single drug. J Clin Oncol 5:1928–1932, 1987
Muggia FM, Chan KK, Tulpule A, Retzios A: Importance of clinical pharmacokinetics for developing new therapies in the U.S.A. In: Kimura K (ed) Seventh Nagoya Symposium on Cancer Treatment: Cancer Chemotherapy — Challenges for the Future. Excerpta Medica, Tokyo, 1992, (in press)
Sartorelli AC: Presidential address: role of hypoxic cells in the therapeutic response of solid tumors [extended abstract]. Proc Am Assoc Cancer Res 28:461, 1987
Bates SE: Clinical applications of serum markers. Ann Intern Med 115:623–638, 1991
Levine MN, Guyatt GH, Gent M, De Pauws S, Goodyear MD, Hryniuk WM, Arnold A, Findlay B, Skillings JR, Bramwell VH, Levin L, Bush H, Abu-Zahra H, Kotalik J: Quality of life in Stage II breast cancer: an instrument for clinical trials. J Clin Oncol 6:1798–1810, 1988
Warrell RP, Murphy WK, Schulman P, O'Dwyer P, Heller G: A randomized double-blind study of gallium nitrate compared with etidronate for acute control of cancer-related hypercalcemia. J Clin Oncol 9:1467–1475, 1991
Lippman ME, Dickson RB, Gelmann EP, Rosen N, Kaufman D, Knabbe C, Bates S, Kasid A, Salomon D, Bronzert D, Huff K: Growth regulation of normal and malignant mammary epithelium [extended abstract]. Proc Am Assoc Cancer Res 28:470–471, 1987
Henderson IC: Window of opportunity [editorial]. J Natl Cancer Inst 83:393–394, 1991
Henderson BE: The Richard and Hinda Rosenthal Foundation Award Lecture: estrogens as a cause of human cancer [extended abstract]. Proc Am Assoc Cancer Res 28:462, 1987
Author information
Authors and Affiliations
Additional information
Held at the 14th Annual San Antonio Breast Cancer Symposium, December 5, 1991, and supported by an educational grant from Bristol-Myers Oncology Division, Evansville, IN, USA.
Rights and permissions
About this article
Cite this article
Muggia, F.M. Managing breast cancer in an outpatient setting. Breast Cancer Res Tr 21, 27–34 (1992). https://doi.org/10.1007/BF01811961
Issue Date:
DOI: https://doi.org/10.1007/BF01811961